{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224069","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-05-14T20:15:34+00:00","discovered_at":"2026-05-14T20:17:10.145877+00:00","generated_at":"2026-05-14T20:52:00.919513+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FDA places full clinical hold on Aardvark's ARD-101 IND; HERO and OLE trials paused","bullets":["FDA full clinical hold on IND for ARD-101, affecting Phase 3 HERO trial (AVK-101-301) and OLE trial (AVK-101-302).","Company to unblind accumulated data from 68 HERO patients and 19 OLE patients to inform next steps.","Cash of $91.2M as of March 31, 2026, expected to fund operations into mid-2027.","Active discussions with FDA ongoing to resolve clinical hold and determine path forward."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224069","json":"https://secwatch.observer/filing/0001193125-26-224069.json","markdown":"https://secwatch.observer/filing/0001193125-26-224069.md","text":"https://secwatch.observer/filing/0001193125-26-224069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526224069/0001193125-26-224069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526224069/ck0001774857-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:52:00.919513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}